SCB
NBIX icon

Saudi Central Bank’s Neurocrine Biosciences NBIX Stock Holding History

Saudi Central Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
6,674
+2,994
+81% +$444K 0.01% 446
2026
Q1 		$485K Buy
+3,680
New +$488K 0.01% 469
2025
Q2 		– Sell
-40
Closed -$4.42K – 373
2025
Q1 		$4.42K Buy
+40
New +$5.07K 0.02% 498

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Saudi Central Bank's NBIX Position: Q2 2026 in Review

Saudi Central Bank increased its Neurocrine Biosciences (NBIX) stake by 81% in Q2 2026, buying an estimated $444K and bringing the position to 6,674 shares worth $1.12M. The position accounts for 0.01% of the portfolio, ranked #446.

Saudi Central Bank first reported a position in NBIX in Q1 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Saudi Central Bank held 6,674 shares of Neurocrine Biosciences worth $1.12M as of Q2 2026.
  • Saudi Central Bank bought 2,994 Neurocrine Biosciences shares in Q2 2026, an estimated $444K.
  • Neurocrine Biosciences made up 0.01% of Saudi Central Bank's portfolio in Q2 2026, its #446 holding.
  • Saudi Central Bank first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Saudi Central Bank's 13F filing for Q2 2026, filed 30 Jul 2026.